Eculizumab for treatment of asthma

Bibliography

• Public Health Agency of Canada. Life and Breath: Respiratory Disease in Canada. Public Health Agency of Canada; Ottawa: 2007
   Google Scholar
• Sporik R, Holgate ST, Platts-Mills TA, Cogswell JJ. Exposure to house-dust mite allergen (Der p I) and the development of asthma in childhood. A prospective study. N Engl J Med 1990;323:502-7
   PubMed Web of Science ®Google Scholar
• Nelson HS. The importance of allergens in the development of asthma and the persistence of symptoms. J Allergy Clin Immunol 2000;105:S628-32
   PubMed Web of Science ®Google Scholar
• Gauvreau GM, Watson RM, O'Byrne PM. Kinetics of allergen-induced airway eosinophilic cytokine production and airway inflammation. Am J Respir Crit Care Med 1999;160:640-7
   PubMed Web of Science ®Google Scholar
• Cockcroft DW, Hargreave FE, O'Byrne PM, Boulet LP. Understanding allergic asthma from allergen inhalation tests. Can Respir J 2007;14:414-18
   PubMed Web of Science ®Google Scholar
• Ward PA. The dark side of C5a in sepsis. Nat Rev Immunol 2004;4:133-42
   PubMed Web of Science ®Google Scholar
• Ffrench-Constant C. Pathogenesis of multiple sclerosis. Lancet 1994;343:271-5
   PubMed Web of Science ®Google Scholar
• Hawlisch H, Wills-Karp M, Karp CL, Kohl J. The anaphylatoxins bridge innate and adaptive immune responses in allergic asthma. Mol Immunol 2004;41:123-31
   PubMed Web of Science ®Google Scholar
• Guo RF, Ward PA. Role of C5a in inflammatory responses. Annu Rev Immunol 2005;23:821-52
   PubMed Web of Science ®Google Scholar
• Hasegawa K, Tamari M, Shao C, Variations in the C3, C3a receptor, and C5 genes affect susceptibility to bronchial asthma. Hum Genet 2004;115:295-301
   PubMed Web of Science ®Google Scholar
• The Collaborative Study on the Genetics of Asthma (CSGA). A genome-wide search for asthma susceptibility loci in ethnically diverse populations. Nat Genet 1997;15:389-92
   PubMed Web of Science ®Google Scholar
• Teran LM, Campos MG, Begishvilli BT, Identification of neutrophil chemotactic factors in bronchoalveolar lavage fluid of asthmatic patients. Clin Exp Allergy 1997;27:396-405
   PubMed Web of Science ®Google Scholar
• Krug N, Tschernig T, Erpenbeck VJ, Complement factors C3a and C5a are increased in bronchoalveolar lavage fluid after segmental allergen provocation in subjects with asthma. Am J Respir Crit Care Med 2001;164:1841-3
   PubMed Web of Science ®Google Scholar
• Strinich TX, Wang Y, Watson RM, Levels of C5a increase in sputum following allergen challenge. Am J Respir Crit Care Med 2007;175:A835
   Google Scholar
• Andersson M, Michel L, Llull JB, Pipkorn U. Complement activation on the nasal mucosal surface–a feature of the immediate allergic reaction in the nose. Allergy 1994;49:242-5
   PubMed Web of Science ®Google Scholar
• Gonczi Z, Varga L, Hidvegi T, The severity of clinical symptoms in ragweed-allergic patients is related to the extent of ragweed-induced complement activation in their sera. Allergy 1997;52:1110-14
   PubMed Web of Science ®Google Scholar
• Nagata S, Glovsky MM. Activation of human serum complement with allergens. I. Generation of C3a, C4a, and C5a and induction of human neutrophil aggregation. J Allergy Clin Immunol 1987;80:24-32
   PubMed Web of Science ®Google Scholar
• Maruo K, Akaike T, Ono T, Generation of anaphylatoxins through proteolytic processing of C3 and C5 by house dust mite protease. J Allergy Clin Immunol 1997;100:253-60
   PubMed Web of Science ®Google Scholar
• Drouin SM, Kildsgaard J, Haviland J, Expression of the complement anaphylatoxin C3a and C5a receptors on bronchial epithelial and smooth muscle cells in models of sepsis and asthma. J Immunol 2001;166:2025-32
   PubMed Web of Science ®Google Scholar
• Johnson AR, Hugli TE, Muller-Eberhard HJ. Release of histamine from rat mast cells by the complement peptides C3a and C5a. Immunology 1975;28(6):1067-80
   PubMed Web of Science ®Google Scholar
• Snyderman R, Phillips J, Mergenhagen SE. Polymorphonuclear Leukocyte Chemotactic activity in rabbit serum and guinea pig serum treated with immune complexes: evidence for C5a as the major chemotactic factor. Infect Immun 1970;1:521-5
   PubMedGoogle Scholar
• Morita E, Schroder JM, Christophers E. Differential sensitivities of purified human eosinophils and neutrophils to defined chemotaxins. Scand J Immunol 1989;29(6):709-16
   PubMed Web of Science ®Google Scholar
• Becker EL. The relationship of the chemotactic behavior of the complement-derived factors, C3a, C5a, and C567, and a bacterial chemotactic factor to their ability to activate the proesterase 1 of rabbit polymorphonuclear leukocytes. J Exp Med 1972;135:376-87
   PubMed Web of Science ®Google Scholar
• Hook WA, Siraganian RP, Wahl SM. Complement-induced histamine release from human basophils. I. Generation of activity in human serum. J Immunol 1975;114:1185-90
   PubMed Web of Science ®Google Scholar
• McCarthy K, Henson PM. Induction of lysosomal enzyme secretion by alveolar macrophages in response to the purified complement fragments C5a and C5a des-arg. J Immunol 1979;123:2511-17
   PubMed Web of Science ®Google Scholar
• Kikuchi Y, Kaplan AP. A role for C5a in augmenting IgG-dependent histamine release from basophils in chronic urticaria. J Allergy Clin Immunol 2002;109:114-18
   PubMed Web of Science ®Google Scholar
• Peng T, Hao L, Madri JA, Role of C5 in the development of airway inflammation, airway hyperresponsiveness, and ongoing airway response. J Clin Invest 2005;115:1590-600
   PubMed Web of Science ®Google Scholar
• McKinley L, Kim J, Bolgos GL, Allergens induce enhanced bronchoconstriction and leukotriene production in C5 deficient mice. Respir Res 2006;7:129
   PubMedGoogle Scholar
• Kodani M, Sakata N, Takano Y, Intratracheal administration of anaphylatoxin C5a potentiates antigen-induced pulmonary reactions through the prolonged production of cysteinyl-leukotrienes. Immunopharmacology 2000;49(3):263-74
   PubMedGoogle Scholar
• Abe M, Shibata K, Akatsu H, Contribution of anaphylatoxin C5a to late airway responses after repeated exposure of antigen to allergic rats. J Immunol 2001;167:4651-60
   PubMed Web of Science ®Google Scholar
• Lukacs NW, Glovsky MM, Ward PA. Complement-dependent immune complex-induced bronchial inflammation and hyperreactivity. Am J Physiol Lung Cell Mol Physiol 2001;280:L512-18
   PubMed Web of Science ®Google Scholar
• Baelder R, Fuchs B, Bautsch W, Pharmacological targeting of anaphylatoxin receptors during the effector phase of allergic asthma suppresses airway hyperresponsiveness and airway inflammation. J Immunol 2005;174:783-9
   PubMed Web of Science ®Google Scholar
• Kohl J, Baelder R, Lewkowich IP, A regulatory role for the C5a anaphylatoxin in type 2 immunity in asthma. J Clin Invest 2006;116:783-96
   PubMed Web of Science ®Google Scholar
• Drouin SM, Sinha M, Sfyroera G, A protective role for the fifth complement component (c5) in allergic airway disease. Am J Respir Crit Care Med 2006;173:852-7
   PubMed Web of Science ®Google Scholar
• Zhang X, Kohl J. A complex role for complement in allergic asthma. Expert Rev Clin Immunol 2010;6(2):269-77
   PubMed Web of Science ®Google Scholar
• Zdanowicz MM. Pharmacotherapy of asthma. Am J Pharm Educ 2007;71:98
   PubMed Web of Science ®Google Scholar
• Desai D, Siddiqui S, Brightling C. Can inhaled corticosteroids prevent asthma exacerbations? Curr Opin Pulm Med 2011;17:16-22
   PubMed Web of Science ®Google Scholar
• Green RH, Brightling CE, Woltmann G, Analysis of induced sputum in adults with asthma: identification of subgroup with isolated sputum neutrophilia and poor response to inhaled corticosteroids. Thorax 2002;57:875-9
   PubMed Web of Science ®Google Scholar
• Strek ME. Difficult asthma. Proc Am Thorac Soc 2006;3:116-23
   PubMedGoogle Scholar
• Leung DY, Spahn JD, Szefler SJ. Steroid-unresponsive asthma. Semin Respir Crit Care Med 2002;23:387-98
   PubMed Web of Science ®Google Scholar
• Berry M, Morgan A, Shaw DE, Pathological features and inhaled corticosteroid response of eosinophilic and noneosinophilic asthma. Thorax 2007;62:1043-9
   PubMed Web of Science ®Google Scholar
• Nelson HS, Weiss ST, Bleecker ER, The salmeterol multicenter asthma research trial: a comparison of usual pharmacotherapy for asthma or usual pharmacotherapy plus salmeterol. Chest 2006;129:15-26
   PubMed Web of Science ®Google Scholar
• Weatherall M, Wijesinghe M, Perrin K, Meta-analysis of the risk of mortality with salmeterol and the effect of concomitant inhaled corticosteroid therapy. Thorax 2010;65:39-43
   PubMed Web of Science ®Google Scholar
• Busse W, Raphael GD, Galant S, Low-dose fluticasone propionate compared with montelukast for first-line treatment of persistent asthma: a randomized clinical trial. J Allergy Clin Immunol 2001;107:461-8
   PubMed Web of Science ®Google Scholar
• Nelson HS, Busse WW, Kerwin E, Fluticasone propionate/salmeterol combination provides more effective asthma control than low-dose inhaled corticosteroid plus montelukast. J Allergy Clin Immunol 2000;106:1088-95
   PubMed Web of Science ®Google Scholar
• Walker S, Monteil M, Phelan K, Anti-IgE for chronic asthma in adults and children. Cochrane Database Syst Rev 2006(2):CD003559
   PubMed Web of Science ®Google Scholar
• Flood-Page P, Swenson C, Faiferman I, A study to evaluate safety and efficacy of mepolizumab in patients with moderate persistent asthma. Am J Respir Crit Care Med 2007;176:1062-71
   PubMed Web of Science ®Google Scholar
• Haldar P, Brightling CE, Hargadon B, Mepolizumab and exacerbations of refractory eosinophilic asthma. N Engl J Med 2009;360:973-84
   PubMed Web of Science ®Google Scholar
• Nair P, Pizzichini MM, Kjarsgaard M, Mepolizumab for prednisone dependent asthma with sputum eosinophilia. N Engl J Med 2009;360:985-93
   PubMed Web of Science ®Google Scholar
• Imaoka H, Campbell H, Babirad I, TPI ASM8 reduces eosinophil progenitors in sputum after allergen challenge. Clin Exp Allergy 2011;41:1740-6
   PubMed Web of Science ®Google Scholar
• Gauvreau GM, Boulet LP, Cockcroft DW, The effects of IL-13 blockade on allergen-induced airway responses in mild atopic asthma. Am J Respir Crit Care Med 2011;183(8):1007-14
   PubMed Web of Science ®Google Scholar
• Wenzel S, Wilbraham D, Fuller R, Effect of an interleukin-4 variant on late phase asthmatic response to allergen challenge in asthmatic patients: results of two phase 2a studies. Lancet 2007;370:1422-31
   PubMed Web of Science ®Google Scholar
• Corren J, Busse W, Meltzer EO, A randomized, controlled, phase 2 study of AMG 317, an IL-4Ralpha antagonist, in patients with asthma. Am J Respir Crit Care Med 2010;181:788-96
   PubMed Web of Science ®Google Scholar
• Hillmen P, Young NS, Schubert J, The complement inhibitor eculizumab in paroxysmal nocturnal hemoglobinuria. N Engl J Med 2006;355(12):1233-43
   PubMed Web of Science ®Google Scholar
• Rother RP, Rollins SA, Mojcik CF, Discovery and development of the complement inhibitor eculizumab for the treatment of paroxysmal nocturnal hemoglobinuria. Nat Biotechnol 2007;25:1256-64
   PubMed Web of Science ®Google Scholar
• Hillmen P, Lewis SM, Bessler M, Natural history of paroxysmal nocturnal hemoglobinuria. N Engl J Med 1995;333(19):1253-8
   PubMed Web of Science ®Google Scholar
• Gauvreau GM, Boulet LP, Serverino B, The effect of C5 inhibition by eculizumab on allergen-induced asthmatic responses in patients. Allergy 2009;64:1-98
   Google Scholar
• Brodsky RA, Young NS, Antonioli E, Multicenter phase 3 study of the complement inhibitor eculizumab for the treatment of patients with paroxysmal nocturnal hemoglobinuria. Blood 2007;111(4):1840-7
   PubMed Web of Science ®Google Scholar
• Risitano AM, Notaro R, Luzzatto L, Paroxysmal nocturnal hemoglobinuria–hemolysis before and after eculizumab. N Engl J Med 2010;363(23):2270-2
   PubMed Web of Science ®Google Scholar
• Kanakura Y, Ohyashiki K, Shichishima T, Safety and efficacy of the terminal complement inhibitor eculizumab in Japanese patients with paroxysmal nocturnal hemoglobinuria: the AEGIS clinical trial. Int J Hematol 2011;93(1):36-46
   PubMed Web of Science ®Google Scholar
• Kim JS, Lee JW, Kim BK, The use of the complement inhibitor eculizumab (Soliris®) for treating Korean patients with paroxysmal nocturnal hemoglobinuria. Korean J Hematol 2010;45(4):269-74
   PubMedGoogle Scholar
• Baas DC, Ho L, Ennis S, The complement component 5 gene and age-related macular degeneration. Ophthalmology 2010;117(3):500-11
   PubMed Web of Science ®Google Scholar
• Lockington D, Imrie F, Gillen J, Visual improvement in established central retinal vein occlusion with long-standing macular edema following systemic eculizumab treatment. Can J Ophthalmol 2010;45(6):649
   PubMed Web of Science ®Google Scholar
• Wang Y, Rollins SA, Madri JA, Matis LA. Anti-C5 monoclonal antibody therapy prevents collagen-induced arthritis and ameliorates established disease. Proc Natl Acad Sci USA 1995;92(19):8955-9
   PubMed Web of Science ®Google Scholar
• Lapeyraque AL, Fremeaux-Bacchi V, Robitaille P. Efficacy of eculizumab in a patient with factor-H-associated atypical haemolytic uremic syndrome. Pediatr Nephrol 2011;26(4):621-4
   PubMed Web of Science ®Google Scholar
• Monk PN, Scola AM, Madala P, Fairlie DP. Function, structure and therapeutic potential of complement C5a receptors. Br J Pharmacol 2007;152:429-48
   PubMed Web of Science ®Google Scholar
• Dmytrijuk A, Robie-Suh K, Cohen MH, FDA report: eculizumab (Soliris) for the treatment of patients with paroxysmal nocturnal hemoglobinuria. Oncologist 2008;13(9):993-1000
   PubMed Web of Science ®Google Scholar